EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Longitudinal analysis of PD-L1 expression in patients with relapsed NSCLC

Nikolaus John, Verena Schlintl, Teresa Sassmann, Jörg Lindenmann, Melanie Fediuk, Robert Wurm, Philipp Douschan, Martin Zacharias, Lipika Kalson, Florian Posch, Gudrun Absenger, Luka Brcic und 2 weitere

Journal for ImmunoTherapy of Cancer · 2024

DOI: 10.1136/jitc-2023-008592 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2024. Verfasst von Nikolaus John und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pulmonology, Department of Internal Medicine, Medical University of Graz, Graz, Austria. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Small Cell Lung Carcinoma. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The use and approval of immune checkpoint inhibitors for the treatment of non-small cell lung cancer (NSCLC) depends on PD-L1 expression in the tumor tissue. Nevertheless, PD-L1 often fails to predict response to treatment. One possible explanation could be a change in PD-L1 expression during the course of the disease and the neglect of reassessment. The purpose of this study was a longitudinal analysis of PD-L1 expression in patients with relapsed NSCLC.

Methods

We retrospectively analyzed PD-L1 expression in patients with early-stage NSCLC and subsequent relapse in preoperative samples, matched surgical specimens and biopsy samples of disease recurrence. Ventana PD-L1 (SP263) immunohistochemistry assay was used for all samples. PD-L1 expression was scored based on clinically relevant groups (0%, 1%–49%, and ≥50%). The primary endpoint was the change in PD-L1 score group between preoperative samples, matched surgical specimens and relapsed tumor tissue.

Results

395 consecutive patients with stages I–III NSCLC and 136 (34%) patients with a subsequent relapse were identified. For 87 patients at least two specimens for comparison of PD-L1 expression between early stage and relapsed disease were available. In 72 cases, a longitudinal analysis between preoperative biopsy, the surgically resected specimen and biopsy of disease recurrence was feasible. When comparing preoperative and matched surgical specimens, a treatment-relevant conversion of PD-L1 expression group was found in 25 patients (34.7%). Neoadjuvant treatment showed no significant effect on PD-L1 alteration (p=0.39). In 32 (36.8%) out of 87 cases, a change in PD-L1 group was observed when biopsies of disease relapse were compared with early-stage disease. Adjuvant treatment was not significantly associated with a change in PD-L1 expression (p=0.53). 39 patients (54.2%) showed at least 1 change into a different PD-L1 score group during the course of disease. 14 patients (19.4%) changed the PD-L1 score group twice, 5 (6.9%) of them being found in all different score groups.

Conclusion

PD-L1 expression shows dynamic changes during the course of disease. There is an urgent need for consensus guidelines to define a PD-L1 testing strategy including time points of reassessment, the number of biopsies to be obtained and judgment of surgical specimens.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsSmall Cell Lung CarcinomaHumansB7-H1 AntigenRetrospective StudiesNeoplasm Recurrence, LocalRecurrence

Stichwörter der Autor:innen

BiomarkerImmune Checkpoint InhibitorLung Cancer

Substanzen

B7-H1 Antigen

Autor:innen und Institutionen

  • Division of Pulmonology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
  • Division of Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
  • Division of Thoracic Surgery, Department of Surgery, Medical University of Graz, Graz, Austria.
  • Department of Internal Medicine, Marburg Lung Center, Giessen, Germany.
  • Diagnostic and Research Institute of Pathology, Medical University of Graz, Graz, Austria.
  • Division of Hematology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.

ORCID-Profile: Angelika Terbuch

Zitieren

APA

John, N., Schlintl, V., Sassmann, T., Lindenmann, J., Fediuk, M., Wurm, R., Douschan, P., Zacharias, M., Kalson, L., Posch, F., Absenger, G., Brcic, L., Jost, P. J., & Terbuch, A. (2024). Longitudinal analysis of PD-L1 expression in patients with relapsed NSCLC. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2023-008592

Vancouver

John N, Schlintl V, Sassmann T, Lindenmann J, Fediuk M, Wurm R, et al. Longitudinal analysis of PD-L1 expression in patients with relapsed NSCLC. Journal for ImmunoTherapy of Cancer. 2024. doi:10.1136/jitc-2023-008592

BibTeX
@article{John2024,
  author = {John, Nikolaus and Schlintl, Verena and Sassmann, Teresa and Lindenmann, Jörg and Fediuk, Melanie and Wurm, Robert and Douschan, Philipp and Zacharias, Martin and Kalson, Lipika and Posch, Florian and Absenger, Gudrun and Brcic, Luka and Jost, Philipp J and Terbuch, Angelika},
  title = {Longitudinal analysis of PD-L1 expression in patients with relapsed NSCLC},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2024},
  doi = {10.1136/jitc-2023-008592}
}
Kostenlos starten →